CN104605344A - Health food for enhancing immunity and preparation method of health food - Google Patents
Health food for enhancing immunity and preparation method of health food Download PDFInfo
- Publication number
- CN104605344A CN104605344A CN201510002692.8A CN201510002692A CN104605344A CN 104605344 A CN104605344 A CN 104605344A CN 201510002692 A CN201510002692 A CN 201510002692A CN 104605344 A CN104605344 A CN 104605344A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- preparation
- medicine composition
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 230000036039 immunity Effects 0.000 title abstract description 17
- 230000002708 enhancing effect Effects 0.000 title abstract description 5
- 235000013402 health food Nutrition 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 89
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 52
- 241000270708 Testudinidae Species 0.000 claims abstract description 35
- 239000000052 vinegar Substances 0.000 claims abstract description 35
- 235000021419 vinegar Nutrition 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 31
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 27
- 241000405414 Rehmannia Species 0.000 claims abstract description 27
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 28
- 240000000249 Morus alba Species 0.000 claims description 23
- 241001165494 Rhodiola Species 0.000 claims description 22
- 244000111489 Gardenia augusta Species 0.000 claims description 21
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- -1 pulvis Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 9
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 235000020985 whole grains Nutrition 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940080313 sodium starch Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 abstract description 15
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000572565 Alpinia oxyphylla Species 0.000 abstract 1
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 241000218231 Moraceae Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 67
- 239000000284 extract Substances 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 230000006870 function Effects 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 17
- 230000000242 pagocytic effect Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000036737 immune function Effects 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 150000004676 glycans Chemical class 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 229920001282 polysaccharide Polymers 0.000 description 14
- 239000005017 polysaccharide Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 8
- 108010006464 Hemolysin Proteins Proteins 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003228 hemolysin Substances 0.000 description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000643 oven drying Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000007306 turnover Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- NYCXYIWXBJWWIL-PZYDOOQISA-N (2s,3r,4s,5s,6r)-2-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,4,5,5a,6,6a-hexahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2CCO1 NYCXYIWXBJWWIL-PZYDOOQISA-N 0.000 description 2
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 2
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000157 blood function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- NYCXYIWXBJWWIL-UHFFFAOYSA-N dihydrocatalpol Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2CCO1 NYCXYIWXBJWWIL-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- YOOQXBIEVFLKNS-UHFFFAOYSA-N Acetylcatalpol Natural products CC(=O)OCC12OC1C(O)C3C=COC(OC4OC(CO)C(O)C(O)C4O)C23 YOOQXBIEVFLKNS-UHFFFAOYSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- VDWSYBFEQXWINA-UHFFFAOYSA-N Martinoside Natural products C1=C(O)C(OC)=CC=C1CCOC1C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(OC(=O)C=CC=2C=C(O)C(OC)=CC=2)C(CO)O1 VDWSYBFEQXWINA-UHFFFAOYSA-N 0.000 description 1
- 241000034042 Mauremys reevesii Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- WLWAYPFRKDSFCL-CNMJWYMJSA-N [(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC=C1CCO[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)[C@@H](CO)O1 WLWAYPFRKDSFCL-CNMJWYMJSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- RLGRBYHBNWLGER-UHFFFAOYSA-N cistanoside D Natural products C1=C(O)C(OC)=CC(CCOC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(OC(=O)C=CC=3C=C(OC)C(O)=CC=3)C(CO)O2)O)=C1 RLGRBYHBNWLGER-UHFFFAOYSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- ZMYQRHSOVRDQDL-NSWBACJASA-N leucosceptoside A Natural products COc1cc(C=CC(=O)O[C@@H]2[C@@H](CO)O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@H]2O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)ccc1O ZMYQRHSOVRDQDL-NSWBACJASA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WLWAYPFRKDSFCL-AYPSUWEUSA-N martynoside Natural products COc1ccc(CCO[C@@H]2O[C@H](CO)[C@@H](OC(=O)C=Cc3ccc(O)c(OC)c3)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@H]2O)cc1O WLWAYPFRKDSFCL-AYPSUWEUSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- WVHRUHMGDQLMBZ-NQZYIAJFSA-N monomelittoside Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@]2(O)[C@H](O)C=C(CO)[C@@H]12 WVHRUHMGDQLMBZ-NQZYIAJFSA-N 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000000955 splenic vein Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for enhancing immunity. The traditional Chinese medicine composition for enhancing immunity is prepared through the following steps: taking prepared rehmannia root, tortoise shell prepared with vinegar, glossy privet fruits, rhodiola rosea, mulberries, alpinia oxyphylla and gardenia as raw materials, extracting, concentrating, drying and adding auxiliary materials according to a certain ratio. The composition preparation has the function of enhancing the immunity.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of develop immunitypty, particularly a kind of is Chinese medicine preparation composition prepared by bulk drug by prepared rhizome of rehmannia, vinegar tortoise plastron, the fruit of glossy privet, rhodiola root, fructus alpiniae oxyphyllae, mulberry fruit, cape jasmine.
Technical background
Body immunity comes in the immune system of self, and immune system is made up of immune organ, immunocyte and immune factor.Immunocyte, immune factor distribution whole body, seething, form a network mutually restricted, the immunologic function dominating human body resists bacterium, poisoning intrusion, the cell of damage sex change and aging in purged body, purged body intracellular metabolite refuse, maintains the stable of organismic internal environment.
Along with the develop rapidly of economy, the rhythm of life of people accelerates, and nervous, overtime work stays up late phenomenon generally, and shorten the length of one's sleep, the not high immunity of organisms that causes of sleep quality declines, easy catching a cold, endocrinopathy in addition.Immunocompromised patients also easily infects tuberculosis.
Modern study finds, much Chinese medicine all has immunoregulation effect.In vitro and in vivo experiment all shows, be no matter that single medicine or prescription all can affect the secretion of cell factor, the release of histamine, the synthesis of immunoglobulin (Ig) and type conversion, the expression of cell surface receptor, lymphocyte proliferation test, have therapeutic action to infection and tumour.
In the five internal organs of the traditional Chinese medical science, the relation of spleen and kidney and immunity is very close, and the kidney being the origin of congenital constitution, the root of the five internal organs, the door of life.Kidney qi foot, health is good for, and the immunologic function of body is just normal; Kidney qi declines, the positive deficiency of vital energy, and the immunologic function of body is just low.The traditional Chinese medical science proposes " the spleen being the foundation of acquired constitution, source of generating QI and blood ", and " The spleen has the function to transport and transform nutrients ", this and microecological balance have close inner link.Harmonizing the spleen and stomach and adjustment microecological balance, the immunity improving body is closely related.Modern to spleen, the experimental study of suffering from a deficiency of the kidney, confirm spleen, suffer from a deficiency of the kidney consistent with immunologic hypofunction degree, theory of traditional Chinese medical science suffer from a deficiency of the kidney most notably, be also that immunologic function damages most severe patient.
Invigorating the spleen, kidney tonifying etc. is had to the influential Chinese traditional treatment method of immunity.
In this product prescription, prepared rhizome of rehmannia has enriching yin of enriching blood, and beneficial essence fills out marrow function, and the fruit of glossy privet has nourishing liver and kidney function, fructus alpiniae oxyphyllae has warm kidney controlling nocturnal emission with astringent drugs function, and tortoise plastron has enriching yin, and nourish blood function, mulberry fruit has nourishing yin and supplementing blood function, is therefore nourished blood by replenishing vital essence to tonify kidney, and beneficial essence is filled out marrow and carried out develop immunitypty; Rhodiola root has qi and activate blood circulation function, and fructus alpiniae oxyphyllae also has warm splenic function, warm spleen qi and activate blood circulation, again can develop immunitypty; Cape jasmine can let out fiery relieving restlessness, clearing heat and promoting diuresis, removing pattogenic heat from the blood and toxic material from the body, can avoid the greasy stomach that hinders of taste in the nourishings such as prepared rhizome of rehmannia, prepared rhizome of rehmannia can be made to play nourishing yin and supplementing blood better, expel the heat-evil simultaneously and deposit the moon.This product kidney tonifying temperature spleen, the first day after tomorrow also mends, and also fills blood, reaches strengthening vital QI to eliminate pathogenic factors object, develop immunitypty.
Prepared rhizome of rehmannia: prepared rhizome of rehmannia be Scrophulariaceae herbaceos perennial glutinous rehmannia dried root through steeping in wine mix steam after drier person obtain.Prepared rhizome of rehmannia contains multiple methods of glycosides, based on iridoid glycosides, as Catalpol (catalpol), dihydro Catalpol (dihydrocatalpol), acetylcatalpol, aucubin (aucubin), single close Z-TEK glycosides (danmelittoside), martynoside A, B, C, D (rehmanniosideA, B, C, D) etc.Containing 8 kinds of saccharide compounds such as Dihuang polysaccharide RPS-b, stachyose, gossypose, glucose, sucrose, fructose, manninotrioses in prepared rhizome of rehmannia.Prepared rhizome of rehmannia is enriched blood enriching yin, and beneficial essence fills out marrow, sallow for the deficiency of blood, palpitation and severe palpitation, irregular menstruation, metrostaxis, the deficiency of liver-yin and kidney-yin, soreness and weakness of waist and knees, osteopyrexia and fever, and night sweat is passed out semen, and interior heat is quenched one's thirst, dizzy, tinnitus, poliosis.
Modern pharmacological research its on immune impact: be 18% to increment rate after white blood cell count(WBC) medication, enhance the immunologic function of body to a certain extent.Experiment proves, Dihuang polysaccharide can significantly improve the lymphocytic breeder reaction ability of normal mouse T in experiment in vitro in vivo and the long period can maintain higher level, shows obvious immunoregulatory activity.Further research finds, Dihuang polysaccharide has suppression mouse S180 function of tumor, and the generation of this tumor-inhibiting action is relevant with the decline that part improves interleukin 2 (IL-2) secretion capacity with the decline of the vigor reversing cytotoxic T lymphocyte (CTL).Research finds that prepared rhizome of rehmannia water extract and Thick many candies all significantly can promote concanavalin A, the lymphocytic propagation of mouse thymus and spleen before and after stimulating, improve supernatant interleukin 2, interferon-γ, interleukin 4, interleukin 5 level, and present dose-dependent relationship.
Vinegar tortoise plastron: tortoise plastron another name is tortoiseshell, and being dry carapace and the plastron of Testudinidae (Tesrudinidae) animal tortoise Chinemysreevesii (Gray), is the enriching yin medicinal material commonly used simply.Its main component is amino acid.Prove through pharmacological research and Clinical practice, tortoise plastron is put down, and taste is sweet, salty; Have nourishing Yin and falling fire, replenishing kidney and strengthening bone, the function of bushing of nourishing blood.For deficiency of Yin hectic fever, hectic fever due to yin night sweat, consumption of YIN caused by febrile disease, has a dizzy spell, endogenous deficient wind, soreness and weakness of waist and knees, forgetful disease such as grade of having a guilty conscience, and has good curative effect.Xie Yangzhou etc. find that the upper first decocting liquid of tortoise can make the humoral immunity of the rat reduced and cellular immune function be recovered preferably.
The fruit of glossy privet: the fruit of glossy privet is the ripening fruits of Oleaceae Ligustrum plant glossy privet.Chemical composition puts acid, oleic acid, linoleic acid, flavonoids etc. containing polysaccharide, oleanolic acid, palm fibre.Property is sweet, bitter, cool, returns liver, kidney, the heart channel of Hang-Shaoyin.The traditional Chinese medical science tonifies the liver and kidney, black invention order, effect of mental-tranquilization.Current research finds the effects such as the fruit of glossy privet has antitumor, liver protection effect, immunity moderation function, delays senility, anti-inflammatory, reducing blood lipid.Nearest discovery, the fruit of glossy privet can increase immune organ weight, can increase Thymus and spleen index by fruit of glossy privet decoction liquor to mouse gavaging.Fructus Ligustri Lucidi polysaccharide energy regulatory T-cell function, gives mouse peritoneal injection, and SPL can be made to strengthen the breeder reaction that conA stimulates, and 3H-TdR incorporation significantly increases.Experiment in vitro shows, and the fruit of glossy privet obviously can strengthen the lymphopoiesis that suboptimal dose PHA, CO cause, and strengthens the rat local graft versus host reaction that allo-lymphocytes causes.Give S180 tumor-bearing mice and gavage Fructus Ligustri Lucidi polysaccharide every day, continuous 14 days, find that it can promote tumor-bearing mice spleen bone-marrow-derived lymphocyte and the lymphocytic propagation of T, with Yac-1 cell as target cell, find that Fructus Ligustri Lucidi polysaccharide can also improve tumor-bearing mice NK cytoactive and strengthen the phagocytic function of mononuclear macrophage.
With fruit of glossy privet water decoction can make Hemolysin to mouse gavaging, IgG content significantly increases, antagonism ring phosphorus phthalein amine is to the inhibitory action of humoral immunity.
By fruit of glossy privet decoction liquor to mouse gavaging, significantly can strengthen mononuclear macrophage and effect is cleaned up to carbon granules in blood, increase phagocytic rate and the phagocytic index of peritoneal macrophage.
Rhodiola root: be the dry herb of Crassulaceae rhodiola herbaceos perennial rhodiola.Rhodiola root mainly containing rhodioside, tyrosol and Radix Phodiolae Polyose, and contains fat, sterol, phenolic compound, organic acid, tannin, multiple micro-element and water-soluble volatile oil; In addition, 18 seed amino acids such as asparatate, threonine serine, glutamic acid, glycine, alanine, valine, leucine, tyrosine, phenylalanine, lysine, histidine, arginine, proline are also comprised; 35 kinds of inorganic elements such as magnesium, calcium, potassium, phosphorus; The macro-and trace-element iron, aluminium, zinc, cobalt, cadmium, titanium, copper, manganese etc. of 15 kinds of needed by human.Rhodiola root has and strengthens memory, improves cardio-cerebrovascular function, strengthens immunity, antifatigue, resist oxygen lack, antitumor, hypoglycemic, antiviral, resisting microwave radiation, armour from many-sided pharmacological actions such as radical damages.
Zhang Ruxue research finds that Radix Phodiolae Polyose does not make significant difference to mouse peripheral blood leucocyte and thymic weight.Human peripheral blood Hb content has reducing effect at normal mouse, then has castering action at hypoimmunity mice.Radix Phodiolae Polyose can promote that normal mouse Splenic vein hemodynamics reacts and NK cell killing activity, and immune suppressed mouse These parameters can be made again to reverse simultaneously.
Fructus alpiniae oxyphyllae: intelligence development is the ripe dry fruit of Zingiber Alpinia plants intelligence development.Its composition is containing diaryl heptane class, flavonoids, sesquiterpenoids, sterol and methods of glycosides thereof.Traditional effect of intelligence development is warming spleen and stopping diarrhaly take the photograph saliva; warm kidney controlling nocturnal emission with astringent drugs contracting urine; and modern pharmacology research shows; the pharmacological action of intelligence development is far away moreover, also have anticancer, cardiac stimulant, vasodilator, calmness, analgesia, antiallergy, anti-ageing, anti-oxidant, improve many-sided pharmacologically active such as immunity, neuroprotective.The research such as KimSH finds that the water extract part of intelligence development has stronger inhibitory action through abdominal cavity or oral administration to the allergic reaction that immunoglobulin E mediates, abdominal cavity or oral administration, fructus alpiniae oxyphyllae water extract can suppress passive cutaneous anaphylaxis to react, intravenously administrable then shows faint restrictive function, result of study shows that fructus alpiniae oxyphyllae has obvious antianaphylaxis effect, point out that this phenomenon should be relevant with the metabolic pathway of active component in human body simultaneously, this extract shows different activity according to different way of administration, may be caused by different biologically actives.
Mulberry fruit: the ripening fruits of mulberry fruit system Moraceae Morus mulberry tree.Its composition has total reducing sugar 12.00% ~ 15.00%, free acid 1.86%, crude fibre 0.91%, crude protein 0.38%, ash content 0.66%, and the composition such as carrotene, vitamin C, vitamin B1, vitamin B2, rutin, myricetin, morin, anthocyanidin rutin sophorin, tannin, Cyanidin, volatile oil (being mainly Cineole and geraniol) and phosphatide (mainly containing phosphatid ylcholine, lysophosphatidyl choline and phosphatidyl-ethanolamine etc.).
Modern pharmacology experimental study shows that it can strengthen mouse immunity: 100% mulberry fruit decocting liquid, by 10g/kg gastric infusion 10d, has no significant effect normal mouse thymus weight and serum carbonic clearance speed, obviously can increase the weight of spleen.To the body weight of asthenic symptoms mouse caused by hydrocortisone, spleen, thymic weight and serum carbonic clearance speed all have significant increasing action.After same method administration 4d, find that mulberry fruit significantly can increase the serum hemolysin (P<0.01) of asthenic symptoms mouse caused by normal mouse and hydrocortisone, illustrate that it has humidification to humoral immunity.
Chu Wei observes the impact of mulberry fruit on immunologic function from cellular immunity and humoral immunity two aspect, found that: mulberry fruit is in adjustment body non-specific immune function, the phagocytic function of macrophage can be strengthened, compared with control group, its phagocytic index, phagocytic percentage all has marked difference, and (P<0.01, namely mulberry fruit has obvious humidification to Immune Function.
Cape jasmine: cape jasmine is Rubiaceae Gardenia Ellis evergreen shrubs cape jasmine, has another name called fructus gardeniae, Yellow Fructus Gardeniae, HUANGZHIZI etc., main product in Zhejiang, Fujian, Jiangxi, Hunan, Guangdong.The dry mature fruit of cape jasmine is used as medicine and claims cape jasmine.It is containing iridoids, organic acid, volatile oil, flavonoids, triterpenes, Coumarins, other classes.Iridoid constituents is its main component, has the multiple pharmacologically actives such as anti-inflammatory, anti-oxidant, cholagogic, diuresis, antitumor, antipyretic, analgesia, radiation protection, reducing blood lipid.
Summary of the invention
The object of the invention is to Chinese medicine composition of openly a kind of develop immunitypty and preparation method thereof.A kind of Chinese medicine composition of develop immunitypty, it is characterized in that: be prepared from by the Chinese medicine material medicine of following weight proportion, prepared rhizome of rehmannia 500 ~ 1000 parts, vinegar tortoise plastron 500 ~ 1000 parts, the fruit of glossy privet 200 ~ 800 parts, rhodiola root 200 ~ 800 parts, fructus alpiniae oxyphyllae 50 ~ 700 parts, 50 ~ 700 parts, mulberry fruit, cape jasmine 50 ~ 700 parts.
Described Chinese medicine composition, it is characterized in that: be prepared from by the Chinese medicine material medicine of following weight proportion, prepared rhizome of rehmannia 650 ~ 900 parts, vinegar tortoise plastron 650 ~ 900 parts, the fruit of glossy privet 300 ~ 500 parts, rhodiola root 300 ~ 500 parts, fructus alpiniae oxyphyllae 100 ~ 300 parts, 100 ~ 300 parts, mulberry fruit, cape jasmine 100 ~ 300 parts.
The Chinese medicine composition of described energy develop immunitypty, is characterized in that each component with parts by weight is: prepared rhizome of rehmannia 800 parts, vinegar tortoise plastron 800 parts, the fruit of glossy privet 480 parts, rhodiola root 480 parts, fructus alpiniae oxyphyllae 240 parts, 240 parts, mulberry fruit, cape jasmine 200 parts.
Described Chinese medicine composition, it is characterized in that, be selected from tablet, capsule, oral liquid, suck agent, granule, pill, powder, paste, sublimed preparation, supensoid agent, pulvis, solution, injection, mixture, syrup, vina, suppository, pill or patch.
Chinese medicine preparation of the present invention can be any pharmaceutically useful formulation, and these formulations comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, paste, sublimed preparation, supensoid agent, mixture, syrup, vina, pulvis, solution, injection, suppository, ointment, emplastrum, creme, spray, drops, patch.Preparation of the present invention, preferably peroral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, paste etc.Most preferably tablet.
Chinese medicine preparation composition of the present invention, the preparation of its oral administration can containing conventional excipient, and such as adhesive, filler, diluent, tablet agent, lubricant, disintegrant, colouring agent, flavor enhancement and wetting agent, can carry out dressing to tablet if desired.
The filler be suitable for comprises microcrystalline cellulose, mannitol, lactose, calcium monohydrogen phosphate and other similar filler.Suitable disintegrant comprises starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate.Suitable lubricant comprises, such as dolomol, silica.The suitable acceptable wetting agent of medicine comprises lauryl sodium sulfate.
By mixing, fill, the method that compressing tablet etc. are conventional prepares solid oral composition.Repeatedly mix and active material can be made to be distributed in those compositions of a large amount of filler of whole use.
The form of oral liquid can be such as water-based or oily suspensions, solution, emulsion, syrup or elixir, or can be the composite dry products of a kind of available water before use or other suitable carrier.This liquid preparation can containing conventional additive, such as suspending agent, such as sorbierite, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agent, such as lecithin, sorbitan monooleate or Arabic gum; Non-aqueous carrier (they can comprise edible oil), the oily ester of the such as ester of apricot kernel oil, fractionated coconut oil, such as glycerine, propane diols or ethanol; Anticorrisive agent, such as para hydroxybenzene methyl esters or propylparaben or sorbic acid, and if need, can containing conventional flavouring agent or colouring agent.
For injection, the fluid unit dosage form of preparation contains active material of the present invention and sterile carrier.According to carrier and concentration, this compound can be suspended or dissolve.The preparation of solution, normally by being dissolved in by active material in a kind of carrier, being filtered sterilization, then being sealed before being loaded a kind of suitable bottle or ampoule.Auxiliary material such as a kind of local anesthetic, anticorrisive agent and buffer also can be dissolved in this carrier.In order to improve its stability, by freezing for this composition after loading bottle, and under vacuo water can be removed.
Chinese medicine preparation of the present invention, applicable medicine acceptable carrier is optionally added when being prepared into medicament, described medicine acceptable carrier is selected from: sweet mellow wine, sorbierite, sodium pyrosulfite, calcium monohydrogen phosphate, sodium hydrogensulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and its derivates, alginates, gelatin, polyvinylpyrrolidone, glycerine, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surfactant, polyethylene glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, kaolin, talcum powder, calcium stearate, dolomol etc.
Preparation of the present invention according to the situation determination usage and dosage of patient, can take three every day in use, each 1-20 agent, as: 1-20 bag or grain or sheet.
The final drug preparation that of the present invention dose of finger is made, as capsule 1000 doses refers to capsule preparations 1000,1000 doses, tablet refers to 1000, tablet, is granule 1000 grams for granule.Weight can increase or reduce, but the constant rate of raw medicinal herbs weight proportion between each composition.More than composition is by weight as proportioning, can increase according to corresponding proportion when producing or reduce, as large-scale production can by kilogram in units of, or in units of ton, small-scale production also can in units of milligram, weight can increase or reduce, but the constant rate of raw medicinal herbs weight proportion between each composition.Single medicinal material more than in composition, especially ministerial drug and adjutant, also can be replaced by the suitable Chinese medicine with the identical property of medicine, its drug effect of the Chinese medicine preparation after replacement is constant.
The preparation method of described Chinese medicine composition, is characterized in that, step is as follows: vinegar tortoise plastron is pulverized, for subsequent use; All the other Six-element medicinal materials, boiling, filters, and filtrate merges, and reduced pressure concentration, dry, pulverize, and adds vinegar tortoise plastron powder, adds filler, mix, and granulate, whole grain, adds lubricant, mixes, and compressing tablet to obtain final product.
Described Chinese medicine composition preparation method, it is characterized in that, step is as follows: vinegar tortoise plastron boiling three times, and decocting liquid filters, and filtrate merges, stand for standby use; All the other Six-element medicinal materials, boiling secondary, filters, and filtrate merges, and add above-mentioned filtrate for subsequent use, reduced pressure concentration, dry, pulverize, and adds filler, mixes, and granulates, and dry, whole grain, adds lubricant, mixes, compressing tablet, and dressing to obtain final product.
Described Chinese medicine composition preparation method, is characterized in that: by extraction, concentrated, dry, mixing, fill, the method that compressing tablet etc. are commonly used prepares solid oral composition; The preparation of its oral administration can containing conventional excipient; The filler be suitable for comprises microcrystalline cellulose, mannitol, lactose, calcium monohydrogen phosphate and other similar filler; Suitable disintegrant comprises starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate; Suitable lubricant comprises dolomol, silica etc.
Chinese medicinal composition preparation of the present invention, being that the Chinese medicine material by being formed by above-mentioned formula is processed through extraction or other modes, making pharmaceutically active substance, subsequently, with this material for raw material, when needing, add medicine acceptable carrier, make according to the routine techniques of galenic pharmacy.Described active material can obtain by extracting Chinese medicine material respectively, also can be obtained by the common Chinese medicine material that extracts, also can obtain by other means, as: by pulverizing, squeezing, calcine, grind, sieve, diacolation, extraction, water extraction, alcohol extracting, ester carry, the material that method obtains, these active materials can be medicinal extract form such as ketone is carried, chromatography, can be dry extract also can be liquid extract, need to determine to make different concentration according to the difference of preparation.
Pharmaceutically active substance in Chinese medicinal composition preparation of the present invention, its in the formulation shared percentage by weight can be 0.1-99.9%, all the other are medicine acceptable carrier.Pharmaceutical preparation of the present invention, exists in a unit, and described unit dosage form refers to the unit of preparation, as every sheet of tablet, and every capsules of capsule, every bottle of oral liquid, granule every bag etc.
Described Chinese medicine composition can be applied in the medicine preparing develop immunitypty or health products.
Detailed description of the invention:
Further illustrate the present invention below by embodiment, but do not show limiting to the claimed invention.
Prepared by embodiment 1, a kind of Chinese medicine composition
Instrument and reagent
Instrument lambda25 spectrophotometry instrument;
Reagent prepared rhizome of rehmannia, the fruit of glossy privet, rhodiola root, vinegar tortoise plastron, fructus alpiniae oxyphyllae, mulberry fruit, cape jasmine
Reagent glucose control product (Nat'l Pharmaceutical & Biological Products Control Institute provides, for assay); Sulfuric acid, anthrone are pure for analyzing, and water is ultra-pure water.
Method and result
Preparation method of the present invention is through screening acquisition, and screening process is as follows:
1. the research of vinegar tortoise plastron extraction process: with dry extract yield and extract polyoses content for inspection target, experiment investigation is carried out to the extraction process in extraction process.By 3 factors (amount of water, decoction number of times, decocting time) 3 levels, design orthogonal test table L
9(3
4), carry out orthogonal test with this table, experimental result as table 1,2,3.
Table 1 vinegar tortoise plastron extracts research and design
Table 1 orthogonal test gauge outfit L
9(3
4)
Get vinegar tortoise plastron, be ground into most meal, test by orthogonal test arrangement, filter, filtrate reduced in volume, dry, obtain 9 groups of sample dry extracts.
Table 2 orthogonal experiments
The variance analysis of table 3 yield of extract
Results and analysis: experimentally result can be found out, extraction time has remarkable impact to yield of extract, according to intuitive analysis result, optimised process is 10 times amount that add water, and extracts 3 times, each 2 hours, because extraction time and amount of water affect not quite, vinegar tortoise plastron extraction process determines that getting vinegar tortoise plastron powder becomes most meal, extracting in water 3 times, add 6 times of water gagings at every turn, extract 1.5 hours.
2. other 6 taste medicinal material extract technical studies
According to literature search, polysaccharide has stronger enhancing immunization, and in the medicines such as rhodiola root, mulberry fruit, the fruit of glossy privet, prepared rhizome of rehmannia, polysaccharide all has the effect strengthening immunity, take polysaccharide as Testing index, investigate extraction time, amount of water, extraction time to the impact of polysaccharide, determine best extraction process.The results are shown in Table 4, table 5, table 6.
Table 4 orthogonal test gauge outfit L
9(3
4)
Get fructus alpiniae oxyphyllae fragmentation, merge other medicinal materials, test by orthogonal test arrangement, filter, filtrate reduced in volume, dry, obtain 9 groups of sample dry extracts.Measure polysaccharide total amount in medicinal extract according to Thick many candies content assaying method in " health food functional component detection method ", the results are shown in Table 5.
Table 5 orthogonal experiments
The variance analysis of table 6 polysaccharide
α=0.05
Results and analysis: experimental result display extraction time has remarkable impact to Polyose extraction, extraction time and amount of water do not make significant difference to Polyose extraction under the condition of design, and according to intuitive analysis, optimum extraction condition is for getting medicinal material extract 3 times, each extraction 2 hours, adds 10 times of water gagings.
According to variance analysis, self 2 times of water gaging can be absorbed from the saving energy and medicinal material itself and consider, extraction process is modified to: all the other Six-element medicinal materials, boiling secondary, first time adds the soak by water 1.5 hours of 8 times amount, and second time adds 6 times amount soak by water 1 hour, filter, merging filtrate.
3. drying process research: adopt oven drying method, boulton process, micro-wave drying method three kinds of drying means to carry out comparative study respectively.Oven drying method, boulton process carry out the dry comparison of 3 kinds of different temperatures (60 DEG C, 75 DEG C, 90 DEG C) respectively.Using drying time and Determination of Gardenoside as observation index, determine to select boulton process to carry out drying under not higher than 90 DEG C of conditions.
Table 7 drying condition screens
Vacuum drying | Microwave drying | Constant pressure and dry | |
Baking temperature | 60 | 60 | 60 |
Dry cream rate (%) | 49.3 | 49.5 | 49.6 |
Polysaccharide total amount (g) | 3.25 | 3.23 | 3.20 |
Drying time (h) | 4 | 1.6 | 6 |
Results and analysis: experimental result shows drying mode on polyoses content without impact, but microwave drying is fastest, from the viewpoint of production control and energy-conservation, is decided to be microwave drying by drying mode.
4. Study on Forming: because this product is pure Chinese medical extract, have stronger hygroscopicity, considers that adding suitable auxiliary material granulates, to increase the mobility of material, improves the stability of preparation.Ethanol is that wetting agent is granulated, with mouldability, mobility, disintegration time limited for inspection target.Investigate the auxiliary materials such as sodium carboxymethyl starch, HPMC, microcrystalline cellulose (102), calcium monohydrogen phosphate, dolomol, design prescription also investigates disintegration time, specifically in table 8.
Results and analysis: can find out according to 5 prescriptions and disintegration time, the disintegration in medicinal extract sheet of sodium carboxymethyl starch, HPMC is limited in one's ability, the calcium monohydrogen phosphate of cellulose and the mineral matter easily collapsed is adopted obviously to reduce the disintegration time of medicinal extract sheet, experimentally prescription 5 meets this product requirement, therefore adopts prescription 5 as this product prescription.
This product formulation and technology is decided to be: the extraction dried cream powder of recipe quantity medicinal material, microcrystalline cellulose 88g, calcium monohydrogen phosphate 64g, mixing, and the alcohol granulation of 45-85%, 65 DEG C ~ 70 DEG C oven dryings, whole grain, adds 0.5% dolomol, compressing tablet, dressing.
The preparation of embodiment 2, a kind of Chinese medicine composition tablet
Get vinegar tortoise plastron 8 parts (800g), prepared rhizome of rehmannia 8 parts (800g), the fruit of glossy privet 4.8 parts (480g), rhodiola root 4.8 parts (480g), fructus alpiniae oxyphyllae 2.4 parts (240g), 2.4 parts, mulberry fruit (240g), cape jasmine 2 parts (200g), wherein 1 part is 100g.
1) vinegar Carapax Et Plastrum Testudinis extract is prepared:
Vinegar tortoise plastron, be ground into most meal, adding 6 times amount water extractions gets 3 times, each 1.5 hours, releases extract, and merge extract, reduced pressure concentration, obtains vinegar tortoise plastron thick paste for subsequent use.
2) other Six-element medicinal substances extracts are prepared:
Prepared rhizome of rehmannia, the fruit of glossy privet, rhodiola root, fructus alpiniae oxyphyllae, Sang San, cape jasmine are dropped in extractor, add the water of 8 times amount, boil and extract 1.5h, release extract.Add the water of 6 times amount again, boil and extract 1h, release extract, merge aqueous extract, reduced pressure concentration, obtains other Six-element medicinal material thick pastes for subsequent use.
3) merge above-mentioned thick paste, microwave drying, pulverize 80 orders for subsequent use.Extract powder is added microcrystalline cellulose, calcium monohydrogen phosphate to mixer, mix 20 ~ 30 minutes.Add the appropriate amount of ethanol softwood of 45-85%.Make wet granular, be placed in clean pallet.65 DEG C ~ 70 DEG C oven dryings, whole grain.Add dolomol mixing 15 ~ 20 minutes, for subsequent use.Compressing tablet, film coating.
The preparation of embodiment 3, a kind of Chinese medicinal composition granules
Get vinegar tortoise plastron 8 parts (800g), prepared rhizome of rehmannia 8 parts (800g), the fruit of glossy privet 4.8 parts (480g), rhodiola root 4.8 parts (480g), fructus alpiniae oxyphyllae 2.4 parts (240g), 2.4 parts, mulberry fruit (240g), cape jasmine 2 parts (200g).
Wherein 1 part is 100g, prepares vinegar Carapax Et Plastrum Testudinis extract and other Six-element medicinal substances extracts, be prepared into granule according to galenic pharmacy routine techniques according to the method for embodiment 1.
Embodiment 3: the preparation of capsule
Get vinegar tortoise plastron 8 parts (800g), prepared rhizome of rehmannia 8 parts (800g), the fruit of glossy privet 4.8 parts (480g), rhodiola root 4.8 parts (480g), fructus alpiniae oxyphyllae 2.4 parts (240g), 2.4 parts, mulberry fruit (240g), cape jasmine 2 parts (200g).
Wherein 1 part is 100g, prepares vinegar Carapax Et Plastrum Testudinis extract and other Six-element medicinal substances extracts, be prepared into capsule according to galenic pharmacy routine techniques according to the method for embodiment 1.
The preparation of embodiment 4, a kind of Chinese medicine composition oral liquid
Get vinegar tortoise plastron 8 parts (800g), prepared rhizome of rehmannia 8 parts (800g), the fruit of glossy privet 4.8 parts (480g), rhodiola root 4.8 parts (480g), fructus alpiniae oxyphyllae 2.4 parts (240g), 2.4 parts, mulberry fruit (240g), cape jasmine 2 parts (200g).
Wherein 1 part is 100g, prepares vinegar Carapax Et Plastrum Testudinis extract and other Six-element medicinal substances extracts, be prepared into oral liquid according to galenic pharmacy routine techniques according to the method for embodiment 1.
The preparation II of embodiment 5, a kind of Chinese medicine composition tablet
Get vinegar tortoise plastron 8 parts (800g), prepared rhizome of rehmannia 8 parts (800g), the fruit of glossy privet 4.8 parts (480g), rhodiola root 4.8 parts (480g), fructus alpiniae oxyphyllae 2.4 parts (240g), 2.4 parts, mulberry fruit (240g), cape jasmine 2 parts.Wherein 1 part is 100g.
1) vinegar Carapax Et Plastrum Testudinis extract is prepared:
80 orders pulverized by vinegar tortoise plastron, for subsequent use;
2) other Six-element medicinal substances extracts are prepared:
Prepared rhizome of rehmannia, the fruit of glossy privet, rhodiola root, fructus alpiniae oxyphyllae, Sang San, cape jasmine, boiling secondary, first time adds the soak by water 1.5 hours of 8 times amount, second time adds 6 times amount soak by water 1 hour, filter, filtrate merges, and reduced pressure concentration becomes relative density to be the thick paste of 1.05 ~ 1.1 (60 DEG C), 55 DEG C ~ 60 DEG C microwave dryings.
3) extract dried cream powder is broken, adds the vinegar tortoise plastron powder crushed, adds microcrystalline cellulose and calcium monohydrogen phosphate, mix, add 45-85% ethanol 40g, granulate with 24 mesh sieves, 65 DEG C ~ 70 DEG C oven dryings, the whole grain of 20 mesh sieve, add silica, dolomol, mix, compressing tablet, film coating, to obtain final product.
The develop immunitypty function test of experimental example 6, a kind of Chinese medicine composition tablet
Sample: the tablet of energy develop immunitypty of the present invention in Example 2,0.65g/ sheet, after removing dressing, content is sepia, and preparation pharmaceutical composition of the present invention improves immunity function experimental study.Human oral's RD is every day 2 times, each 2, and adult's body weight press 60kg calculating, amounts to dosage 0.0433g/kgbw.
Animal used as test: SPF level ICR mouse 200, female, body weight 18 ~ 22g, the animal used as test quality certification number: No.43004700008193.
Animal used as test is originated: Hunan Si Laike Jing Da animal used as test Co., Ltd, animal used as test production licence number: SCXK (Hunan) 2013-0004.
Regular grade Hartley cavy 30, female, body weight 300 ~ 350g, the animal used as test quality certification number: 2007000702555.
Animal used as test is originated: Shanghai raw prosperous animal used as test cultivation Co., Ltd, animal used as test production licence number: SCXK (Shanghai) 2012-0007.
Feeding environment: barrier environment, room temperature is (20 ~ 25) DEG C, and relative humidity is (40 ~ 70) %.Animal used as test occupancy permit number: SYXK (Jiangxi) 2013-0005.
Feed resource: Beijing Australia of section pulls together feed corporation,Ltd; Feed Manufacturing credit number: SCXK (capital) 2009-0012, SCXK (capital) 2014-0010.
Dosage choice and tested material give mode
Be high, medium and low three dosage groups and negative control group with 30 of human oral's recommended amounts times, 20 times and 10 times, dose design is respectively 1.300g/kgbw, 0.867g/kgbw, 0.433g/kgbw, sample thief 26.00g, 17.34g, 8.66g distilled water is settled to 400ml respectively, give mouse stomach respectively, once a day, gavage volume is 0.2ml/10gbw, and negative control group gives equal-volume distilled water, continuous 30 days.Test method
Above-mentioned tested material gives by body weight every day, continuous 30-45 days, in administration simultaneously, observes the state of animal every day,
Take weekly a weight of animals, and measure indices by the following method.
(1) internal organs/weight ratio pH-value determination pH: after mouse weights record, dislocation is put to death, and gets spleen and thymus gland, removes most manadesma, weigh.Calculate spleen/body weight ratio and thymus gland/body weight ratio.
(2) the mouse spleen lymphocyte transformation experiment (mtt assay) of ConA induction: experiment mice dislocation is put to death, immerse in 75% medicinal alcohol, asepticly get spleen, be placed in the aseptic little mortar filling Hank's liquid, rapidly spleen is ground, make splenocyte suspension, aseptic Hank ' s liquid is used to filter in test tube by cell permeable 6 layers of sterile gauze, 1000rpm, centrifugal 2 times of 10min, abandons supernatant and is upspring by cell, and it is resuspended containing the RPMI1640 complete culture solution of 10% calf serum to add 2mL, spleens cell number is measured, by cell number furnishing experiment desired concn with cell counter.Add in 24 well culture plates by the cell suspension point holes adjusting cell concentration, every hole 1mL, add 50 μ l ConA solution (being equivalent to 5 μ g/ml) wherein in a hole, (5%CO in incubator in contrast, is put in another hole
2, 37 DEG C) cultivate 72 hours.Cultivation terminates first 4 hours, every hole sucks supernatant 0.7mL gently, add 0.7mL not containing the RPMI1640 nutrient solution of calf serum and the MTT/RPMI1640 (5mg/ml) of 50 μ l, continue cultivation 4 hours, cultivate after terminating, every hole adds 1mL acid isopropyl alcohol, purple crystal is dissolved completely, and then moved into by this liquid in 96 hole ELISA Plates, packing 4 holes in each hole are as Duplicate Samples, colorimetric on ELIASA, result represents with the OD value at wavelength 570nm place.Lymphocytic multiplication capacity deducts by the OD value adding ConA hole the OD value not adding ConA hole and represents.
(3) delayed allergy (the sufficient sole of the foot thickens method): every mouse is through lumbar injection 2% (with normal saline) hematocrit SRBC suspension 0.2mL.After immunity 4d, with the left back sufficient sole of the foot thickness (background values) of kind of calliper, same position duplicate measurements three times, calculating mean value.Then at measuring point hypodermic injection 20% hematocrit SRBC, every mouse 20 μ L.After injection, 24h measures left back sufficient sole of the foot thickness again.Pedal swelling degree is represented by the difference of attacking the twice sufficient sole of the foot one-tenth-value thickness 1/10 in front and back.
(4) antibody-producting cell detects: cavy femoral artery (30) is taken a blood sample, isolate serum, it is mixed by 1:5 with hematocrit SRBC, place 30min, frequently shake, 2000rpm for 4 DEG C, 10min centrifuging and taking supernatant, packing ,-30 DEG C of preservations, the used time presses 1:10 dilution with SA buffer solution.Agarose distilled water is mixed with 1% solution, and water-bath is boiled, and makes it to melt completely, is applied on clean slide, for subsequent use in film releasing box after dry.Every mouse is through lumbar injection 2% (preparing with physiological salt liquid) hematocrit SRBC suspension 0.2mL.By immunity 5 days after mouse dislocation put to death, take out spleen, be placed on fill Hank ' s liquid little mortar in, grind, filtered in 10ml test tube by cell with 2 layers of gauze, 1000rpm, 10min are centrifugal, abandon supernatant, wash 1 time with Hank ' s liquid, splenocyte is suspended in 10mLHank ' s liquid for subsequent use.Agarose is mixed with 1% aqueous solution, water-bath is boiled, make it to melt completely, mix with equivalent double Hank ' s liquid, packing small test tube, often pipe 0.5mL, in pipe, add 10% (using SA buffer) hematocrit SRBC suspension 50 μ L, splenocyte suspension 10 μ L again, rapidly after mixing, be poured on agarose thin layer slide, after agar solidification, slide level being buckled is placed on horse, puts into 37oC incubator and hatches 1.5 hours, is then joined by complement in slide frame groove, after continuing to hatch 1.5 hours, counting hemolysis plaque number.Draw 20ul splenocyte suspension, add 10ml cell diluent, fully mix, counting spleens cell number.With plaque number/10
6splenocyte represents.
(5) mensuration (Hemagglutination Method) of serum hemolysin: mouse is through lumbar injection 2% hematocrit SRBC (with normal saline) suspension 0.2mL.Mouse after immune 4-5 days is extractd eyeball, gets whole blood in microcentrifugal tube, leave standstill 1h, 2000r/min, 10min centrifugal, collect serum.With physiological saline by serum doubling dilution, dilution for difference serum is placed in Microhemagglutination brassboard respectively, every hole 100 μ l, add the SRBC suspension of 100 μ l 0.5% (v/v) again, mixing, be loaded in moistening square position and add a cover, in 37 DEG C of incubation 3h, observe hemagglutination degree.
Result antibody product represents.In antibody horizontal=(S1+2S2+3S3nSn) formula 1,2,3n represents the index of two-fold dilution, S represents the rank of aggegation degree, and antibody product is about large, represents that serum antibody is higher.
(6) mouse carbonic clearance test: in the india ink 0.2ml of mouse tail vein injection dilution, treat that prepared Chinese ink injects, immediately timing.Respectively at 2,10 minutes, get blood 20 μ l from left side angular vein clump, and be added to 2mL Na
2cO
3in solution.With Na
2cO
3solution makes blank, with ultraviolet-uisible spectrophotometer at 600nm wavelength place densitometric value (OD).After mouse weights, cervical dislocation is put to death, and gets liver and spleen, removes most manadesma, weigh (g).Calculate phagocytic index.
(7) Turnover of Mouse Peritoneal Macrophages engulfs chicken red blood cells experiment (half intracorporal method): mouse peritoneal injects 20% chicken erythrocyte suspension 1ml, interval is after 30 minutes, inject Hank's liquid 2ml again, mouse is put to death with cervical dislocation, rub belly gently 30 times, fully to wash out peritoneal macrophage, then stomach wall is cut off an osculum, draw abdominal cavity washing lotion 0.5ml with syringe, drip on the slide being decorated with circle.Slide is put into the enamel box being lined with wet gauze, dislocation 37 DEG C of incubator incubations 30 minutes.Hatch after terminating and with Hank's liquid, non-attached cell is washed out rapidly, dry.In methanol solution, fix 5 minutes, Giemsa liquid dyes 20 minutes.Under oily mirror, 100 macrophages are counted to every mouse, engulf in record macrophage the macrophage numbers of chicken red blood cell and macrophage engulf the sum of chicken red blood cell.Be calculated as follows phagocytic index and phagocytic rate:
The macrophage of the sum/counting of chicken red blood cell is engulfed in phagocytic index=macrophage
Macrophage number × 100% of phagocytic rate (%)=the engulf macrophage number/counting of chicken red blood cell
(8) NK cytoactive detection (LDH method): test and target cell YAC-1 was carried out Secondary Culture in first 24 hours, before application, is 1 × 10 with the RPMI1640 complete culture solution adjustment cell concentration containing 10% calf serum
5individual/mL.Mouse cervical dislocation is put to death, and asepticly gets spleen, is placed in the aseptic little mortar filling Hank's liquid, is ground by spleen rapidly, makes splenocyte suspension, with the washing of Hank ' s liquid, and centrifugal 2 times of 1000rpm, 10min.Abandon supernatant to be upspring by sedimentation cell, it is resuspended containing the RPMI1640 complete culture solution of 10% calf serum to add 2mL, measures spleens cell number with cell counter.By cell number furnishing 5 × 10
6individual/ml, makes effect (splenocyte) target (YAC-1) cell than being 50:1.Get target cell and each 100 μ L of effector cell, add in U-shaped 96 porocyte culture plate; Target cell Spontaneous release hole adds target cell and each 100 μ L of nutrient solution, and the maximum release aperture of target cell adds target cell and each 100 μ L of 1%NP40; Above-mentionedly everyly all establish three parallel holes, 37 DEG C, 5%CO
2cultivate 4 hours in incubator.At the end of cultivation, by 96 porocyte culture plates with 1500rpm centrifugal 5 minutes, every hole was drawn supernatant 100 μ L and is put in 96 hole ELISA Plates, add LDH matrix liquid 100 μ L, room temperature reaction 3 minutes, then every hole adds the HCl solution 30 μ L cessation reaction of 1mol/L, surveys OD value at 490nm place with ELIASA.
NK cytoactive %=(reacting hole OD-Spontaneous release hole OD)/(maximum release aperture OD-Spontaneous release hole OD) × 100%
The medicine that Experimental agents uses the embodiment of the present invention 2 to prepare, is called: a kind of Chinese medicine composition alleviating physical fatigue preparation
Experimental result
(1) a Chinese medicine composition develop immunitypty preparation observation that the weight of animals is changed, in table 1,2,3,4,5:
Table 1 Chinese medicine composition develop immunitypty preparation is on the impact of immune I group Mouse Weight:
Table 2 Chinese medicine composition develop immunitypty preparation is on the impact of immune II group Mouse Weight:
Table 3 Chinese medicine composition develop immunitypty preparation is on the impact of immune III group Mouse Weight:
Table 4 Chinese medicine composition develop immunitypty preparation is on the impact of immune IV group Mouse Weight:
Table 5 Chinese medicine composition develop immunitypty preparation is on the impact of immune V group Mouse Weight:
From table 1-5, each dosage group experiment initial stage, experiment mid-term, experiment Mouse Weight in latter stage and the growth of experimental session Mouse Weight are compared with negative control group, there was no significant difference (P>0.05).
(2) a kind of Chinese medicine composition develop immunitypty preparation must affect, in table 6 mouse thymus/weight ratio and spleen/weight ratio:
Table 6 Chinese medicine composition develop immunitypty preparation is on the impact of mouse immune organ internal organs/weight ratio
From table 6: per os gives a kind of Chinese medicine composition develop immunitypty of each dosage group of mouse preparation 30 days, affects (P>0.05) on mouse spleen/body weight ratio and thymus gland/body weight ratio without conspicuousness.
(3) Chinese medicine composition develop immunitypty preparation is on an impact for mouse cell immunologic function,
In table 7,8:
A: the impact that a kind of Chinese medicine composition develop immunitypty preparation is tested mouse ConA induction of lymphocyte conversion capability, in table 7
Table 7 Chinese medicine composition develop immunitypty preparation is to mouse lymphocyte conversion capability experimental result (lymphopoiesis ability)
From table 7: high, medium and low three the dosage groups of a kind of Chinese medicine composition develop immunitypty preparation all can significantly improve mouse lymphocyte conversion capability, have pole significant difference (P<0.01) with the mouse lymphocyte conversion capability of negative control group.
B Chinese medicine composition develop immunitypty preparation on the impact of mouse delayed allergy, in table 8:
Table 8 Chinese medicine composition develop immunitypty preparation is on mouse delayed allergy (the sufficient sole of the foot thickens method) impact (sufficient sole of the foot thickness difference mm)
From table 8: the difference of high, medium and low three dosage groups foot sole of the foot thickness is significantly higher than the difference of negative control group foot sole of the foot thickness, compares P<0.01, P<0.01, P<0.05 respectively with negative control group.
Cellular immune function assay result: mouse lymphocyte transformation experiment result is positive; Delayed allergy (the sufficient sole of the foot thickens method) result is for positive.Cellular immune function assay result is positive.
(4) Chinese medicine composition develop immunitypty preparation is on an impact for humoral immune function, in table 9,10:
A Chinese medicine composition develop immunitypty preparation on the impact of mouse antibodies cellulation, in table 9:
Table 9 Chinese medicine composition develop immunitypty preparation is on mouse antibodies cellulation number impact (plaque number/106 splenocyte)
From table 9: each dosage group plaque number compares with negative control group plaque number, there was no significant difference (P>0.05).
B: a kind of Chinese medicine composition develop immunitypty preparation on the impact of mice serum hemolysin, in table 10:
Table 10 Chinese medicine composition develop immunitypty preparation is on the impact (antibody product) of mice serum hemolysin
From table 10: the antibody product of low dose group is significantly higher than negative control antibody product (P<0.01).Other dosage groups and negative control group there was no significant difference (P>0.05).
Humoral immune function measurement result: antibody-producting cell test experience result is negative, the low dose group result of the mensuration of serum hemolysin is positive.Humoral immune function measurement result is negative.
(5) Chinese medicine composition develop immunitypty preparation is on mouse monokaryon--an impact for macrophage function, see 11,12:
A: a kind of Chinese medicine composition develop immunitypty preparation is on mouse monokaryon--the impact of macrophage carbonic clearance, in table 11:
Table 11 Chinese medicine composition develop immunitypty preparation is on mouse monokaryon--the impact (phagocytic index) of macrophage carbonic clearance
From table 11: high and low two dosage groups can significantly improve mouse carbonic clearance ability, compare with negative control group respectively, P<0.05, P<0.01, middle dosage group compares there was no significant difference (P>0.05) with negative control group.
B: the impact of chicken red blood cell ability engulfed by a kind of Chinese medicine composition develop immunitypty preparation on Turnover of Mouse Peritoneal Macrophages, in table 12:
The impact of chicken red blood cell phagocytic rate engulfed by table 12 Chinese medicine composition develop immunitypty preparation on Turnover of Mouse Peritoneal Macrophages
From table 12: high, medium and low three dosage group phagocytic percentages, phagocytic index compare with negative control group phagocytic percentage, phagocytic index, there was no significant difference (P>0.05).
Monokaryon-macrophage function measurement result: high and low two dosage group results of mouse carbonic clearance experiment are positive.Turnover of Mouse Peritoneal Macrophages engulfs chicken red blood cell experimental result for negative.Monokaryon-macrophage function measurement result is positive.
(6) Chinese medicine composition develop immunitypty preparation is on an impact for NK cells in mice activity, in table 13:
Table 13 Chinese medicine composition develop immunitypty preparation is on the impact of NK cells in mice activity
From table 13: the NK cytoactive of low dose group compares with negative control group NK cytoactive, have significant difference (P<0.05), all the other are group and negative control group there was no significant difference (P>0.05) respectively.
NK cytoactive detection result: in NK cytoactive detection experiment (LDH method), low dose group is positive, and result is positive.NK cytoactive detection result is positive.Result shows:
1. each dosage group compares with negative control group, on Mouse Weight, mouse spleen/body weight and thymus gland/body weight ratio without impact;
2. each dosage group significantly can strengthen mouse delayed allergy and mouse lymphocyte conversion capability;
3. high and low dose group significantly can strengthen mouse carbonic clearance ability;
4. low dose group can significantly improve the content of mice serum hemolysin;
5. low dose group significantly can strengthen the activity of NK cell;
6. each dosage group antagonist cellulation, Turnover of Mouse Peritoneal Macrophages engulf chicken red blood cell function all without impact.
According to develop immunitypty function evaluation regulation in the Ministry of Public Health " health food inspection and assessment technical specification " (version in 2003), comprehensive every result of the test judges, a kind of Chinese medicine composition develop immunitypty sheet has develop immunitypty function.
Claims (8)
1. the Chinese medicine composition of a develop immunitypty, it is characterized in that: be prepared from by the Chinese medicine material medicine of following weight proportion, prepared rhizome of rehmannia 500 ~ 1000 parts, vinegar tortoise plastron 500 ~ 1000 parts, the fruit of glossy privet 200 ~ 800 parts, rhodiola root 200 ~ 800 parts, fructus alpiniae oxyphyllae 50 ~ 700 parts, 50 ~ 700 parts, mulberry fruit, cape jasmine 50 ~ 700 parts.
2. Chinese medicine composition according to claim 1, it is characterized in that: be prepared from by the Chinese medicine material medicine of following weight proportion, prepared rhizome of rehmannia 650 ~ 900 parts, vinegar tortoise plastron 650 ~ 900 parts, the fruit of glossy privet 300 ~ 500 parts, rhodiola root 300 ~ 500 parts, fructus alpiniae oxyphyllae 100 ~ 300 parts, 100 ~ 300 parts, mulberry fruit, cape jasmine 100 ~ 300 parts.
3. the Chinese medicine composition of energy develop immunitypty according to claim 2, is characterized in that each component with parts by weight is: prepared rhizome of rehmannia 800 parts, vinegar tortoise plastron 800 parts, the fruit of glossy privet 480 parts, rhodiola root 480 parts, fructus alpiniae oxyphyllae 240 parts, 240 parts, mulberry fruit, cape jasmine 200 parts.
4. Chinese medicine composition according to claim 1, it is characterized in that, be selected from tablet, capsule, oral liquid, suck agent, granule, pill, powder, paste, sublimed preparation, supensoid agent, pulvis, solution, injection, mixture, syrup, vina, suppository, pill or patch.
5. the preparation method of Chinese medicine composition according to claim 1, is characterized in that, step is as follows: vinegar tortoise plastron is pulverized, for subsequent use; All the other Six-element medicinal materials, boiling, filters, and filtrate merges, and reduced pressure concentration, dry, pulverize, and adds vinegar tortoise plastron powder, adds filler, mix, and granulate, whole grain, adds lubricant, mixes, and compressing tablet to obtain final product.
6. Chinese medicine composition preparation method according to claim 1, it is characterized in that, step is as follows: vinegar tortoise plastron boiling three times, and decocting liquid filters, and filtrate merges, stand for standby use; All the other Six-element medicinal materials, boiling secondary, filters, and filtrate merges, and add above-mentioned filtrate for subsequent use, reduced pressure concentration, dry, pulverize, and adds filler, mixes, and granulates, and dry, whole grain, adds lubricant, mixes, compressing tablet, and dressing to obtain final product.
7. Chinese medicine composition preparation method according to claim 1, is characterized in that: by extraction, concentrated, dry, mixing, fill, the method that compressing tablet etc. are commonly used prepares solid oral composition; The preparation of its oral administration can containing conventional excipient; The filler be suitable for comprises microcrystalline cellulose, mannitol, lactose, calcium monohydrogen phosphate and other similar filler; Suitable disintegrant comprises starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate; Suitable lubricant comprises dolomol, silica etc.
8. the application of Chinese medicine composition in the medicine preparing develop immunitypty or health products of the develop immunitypty of claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510002692.8A CN104605344A (en) | 2015-01-05 | 2015-01-05 | Health food for enhancing immunity and preparation method of health food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510002692.8A CN104605344A (en) | 2015-01-05 | 2015-01-05 | Health food for enhancing immunity and preparation method of health food |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104605344A true CN104605344A (en) | 2015-05-13 |
Family
ID=53140221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510002692.8A Pending CN104605344A (en) | 2015-01-05 | 2015-01-05 | Health food for enhancing immunity and preparation method of health food |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104605344A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105249465A (en) * | 2015-11-19 | 2016-01-20 | 北京世纪合辉医药科技股份有限公司 | Health food capable of improving immunity and preparation method of health food |
CN107136510A (en) * | 2017-07-12 | 2017-09-08 | 延边韩工坊健康制品有限公司 | One kind improves immunity health food and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104908A (en) * | 1994-08-05 | 1995-07-12 | 黄有康 | Nutrient health medicinal liquor |
CN101816739A (en) * | 2010-05-18 | 2010-09-01 | 昆明中药厂有限公司 | Chinese medicinal composition and preparation method thereof |
CN103719498A (en) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | Immunity-enhancing sealwort health-care tea and preparation method thereof |
-
2015
- 2015-01-05 CN CN201510002692.8A patent/CN104605344A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1104908A (en) * | 1994-08-05 | 1995-07-12 | 黄有康 | Nutrient health medicinal liquor |
CN101816739A (en) * | 2010-05-18 | 2010-09-01 | 昆明中药厂有限公司 | Chinese medicinal composition and preparation method thereof |
CN103719498A (en) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | Immunity-enhancing sealwort health-care tea and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105249465A (en) * | 2015-11-19 | 2016-01-20 | 北京世纪合辉医药科技股份有限公司 | Health food capable of improving immunity and preparation method of health food |
CN107136510A (en) * | 2017-07-12 | 2017-09-08 | 延边韩工坊健康制品有限公司 | One kind improves immunity health food and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9694045B2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
CN105999159B (en) | Brown sugar and saussurea involucrata composition and preparation method thereof | |
CN104873624B (en) | A kind of pharmaceutical composition for gouty arthritis | |
CN104940479A (en) | TCM composition for treating AD diseases | |
CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
CN102106965B (en) | Composition for treating acute injury of soft tissue and application thereof | |
KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
CN102048890B (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof | |
CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
CN106535912A (en) | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof | |
CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
CN1840087B (en) | King solomonseal- and fleece-flower root-containing Chinese medicinal formulation for treating chronic fatigue syndrome and its preparation method | |
CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
CN102652819B (en) | Fuyankang dispersible tablet and preparation method thereof | |
CN106690201A (en) | Composition with immunity enhancing function and preparation method thereof | |
JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
CN104352940B (en) | A kind of Chinese medicine composition for alleviating physical fatigue | |
CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
CN106728962B (en) | Pharmaceutical composition for enhancing immunity and application thereof | |
CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150513 |